Physicians specialising in nuclear medicine or nuclear medicine specialists at Aster CMI use radioactive materials for therapeutic and diagnostic reasons. They are skilled at deciphering scans and pictures that show physiological processes occurring within the body, offering perceptions of how different organs and systems operate. Their speciality is the safe administration of radiopharmaceuticals, which emit gamma rays that are picked up by specialised cameras and provide pictures for diagnosis and treatment planning.
Experts in nuclear medicine assess a wide range of symptoms, such as those suggestive of neurological illnesses, oncological problems, endocrine abnormalities, and cardiovascular disease. They concentrate on symptoms like arrhythmias, thyroid dysfunction, seizures, or the presence of cancer that may indicate aberrant organ function.
Nuclear medicine specialists in Bangalore at Aster CMI frequently diagnose patients by evaluating organ function and looking for cellular and molecular disease processes. Techniques such as bone scans, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) aid in the detection of bone diseases, aberrant blood flow, and metabolic alterations.
Advanced imaging technologies used by nuclear medicine specialists at Aster CMI include hybrid imaging systems such as PET/CT and SPECT/CT, gamma cameras, and PET scanners. These devices identify and measure the radiopharmaceutical distribution in the human body. The equipment's ability to see physiological processes and localise functional problems anatomically aids accurate diagnosis and treatment monitoring.
To treat diseases including hyperthyroidism, thyroid cancer, and specific pain syndromes, nuclear medicine specialists in Bangalore at Aster CMI use radiopharmaceuticals to deliver tailored treatments. Thyroid problems are commonly treated with radioactive iodine therapy, whereas bone metastases are treated with radionuclide therapy for pain relief. Furthermore, they may employ targeted cancer therapy with radiolabeled antibodies or peptides, taking advantage of these agents' selectivity to deliver radiation directly to tumour cells.
